With the increasing number of candidate compounds for treating HGPS disease [1, 65], further therapeutic avenues will require the identification of appropriate drug combinations and treatment regimens to target the numerous phenotypic hallmarks that characterize HGPS cells. This evidence concerns the gene LMNA and Hutchinson-Gilford progeria syndrome.